Abstract
BackgroundOlokizumab (OKZ) is an anti-interleukin-6 (IL-6) monoclonal antibody in development for the treatment of rheumatoid arthritis (RA). In phase 2 studies, treatment with OKZ+MTX resulted in significant improvements in disease...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
